Is Anthem Biosciences the Best Stock in Its Sector? A Look at the Numbers

Anthem Biosciences CMP Rs 892 (23 Sep 2026). Market cap Rs 50,236 Cr. ROE 19.45%. P/E 87.26x versus Industry P/E 38.56x.

Updated: 23 Sept 2026 • 10:04 am

Posted by:

Is Anthem Biosciences the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Anthem Biosciences is one of the names investors compare when screening the Healthcare sector, built on a 19.45% return on equity and a P/E of 87.26x against an Industry P/E of 38.56x. Whether Anthem Biosciences is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Anthem Biosciences the best stock in its sector? The stock trades on the NSE at Rs 892 as of 23 September 2026, within its 52-week range of Rs 579.15 to Rs 977.55. Anthem Biosciences Ltd provides contract research, development and manufacturing (CRDMO) services spanning small molecules, biologics and fermentation-based products.

Anthem Biosciences sits in the Healthcare sector, and its 19.45% ROE and 87.26x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Anthem Biosciences

Anthem Biosciences Ltd provides contract research, development and manufacturing (CRDMO) services spanning small molecules, biologics and fermentation-based products. It provides contract research, development and manufacturing (CRDMO) services spanning small molecules, biologics and fermentation-based products for global pharma and biotech clients. At a market capitalisation of Rs 50,236 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Anthem Biosciences the Best Stock in Its Sector?

Anthem Biosciences makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 19.45% ROE with a 87.26x P/E against the sector's 38.56x Industry P/E. Anthem Biosciences' 87.26x P/E is well above the 38.56x Industry P/E and above Sai Life Sciences in this series, a rich premium built on its 19.45% ROE and broad CRDMO capability across small molecules and biologics.

Metric	Anthem Biosciences
CMP (NSE)	Rs 891.70
52-Week High / Low	Rs 977.55 / Rs 579.15
Market Cap	Rs 50,236 Cr
P/E (TTM) vs Industry P/E	87.26x vs 38.56x
P/B	16.51
ROE	19.45%
EPS (TTM)	Rs 10.22
Dividend Yield	0.22%
Debt to Equity	0.02

Compare Anthem Biosciences Against Other Healthcare Sector Stocks

How Anthem Biosciences Compares Against Its Healthcare Sector Peers

The table below sets Anthem Biosciences against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Anthem Biosciences	50,236	87.26	19.45%	0.02
Sai Life Sciences	32,723	90.47	14.05%	0.12
Akums Drugs and Pharmaceuticals	12,059	41.19	7.70%	0.05
Alivus Life Sciences	17,029	28.24	16.94%	0.02
Peer average (3 companies)	-	53.30	12.90%	0.06

Against this peer set, Anthem Biosciences's 19.45% ROE is above the 12.90% peer average, and its P/E of 87.26x runs above the peer average of 53.30x. Anthem Biosciences' 87.26x P/E is well above the 38.56x Industry P/E and above Sai Life Sciences in this series, a rich premium built on its 19.45% ROE and broad CRDMO capability across small molecules and biologics.

What Makes Anthem Biosciences Worth Watching in Healthcare

Strong ROE: A 19.45% ROE is well above most CDMO and API peers covered in this series.
Near debt free: A debt to equity ratio of 0.02 gives Anthem Biosciences flexibility to invest in R&D and manufacturing capacity.
Broad CRDMO capability: Spanning small molecules, biologics and fermentation-based manufacturing gives Anthem Biosciences a wider service range than single-technology CDMO peers.

Anthem Biosciences Valuation: Is It Justified?

Anthem Biosciences' 87.26x P/E is well above the 38.56x Industry P/E and above Sai Life Sciences in this series, a rich premium built on its 19.45% ROE and broad CRDMO capability across small molecules and biologics. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Allied Blenders and Distillers the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Anthem Biosciences and other Healthcare sector stocks.

How to Track Anthem Biosciences Before You Invest

Before deciding whether Anthem Biosciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Anthem Biosciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Anthem Biosciences earns a place in the best stock in its sector conversation on the strength of a 19.45% ROE and a P/E of 87.26x against a 38.56x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Anthem Biosciences the best stock in its sector?

Ans. Anthem Biosciences has a 19.45% ROE and trades at 87.26x P/E against a 38.56x Industry P/E, and compares above the peer average ROE of 12.90% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Anthem Biosciences?

Ans. Anthem Biosciences was trading at Rs 891.70 on the NSE as of 23 September 2026, within its 52-week range of Rs 579.15 to Rs 977.55.

What sector does Anthem Biosciences belong to?

Ans. Anthem Biosciences is classified under the Healthcare sector on Univest.

How does Anthem Biosciences compare to its sector peers on P/E?

Ans. Anthem Biosciences's P/E of 87.26x is above the 53.30x average of the 3 named peers compared in this article.

What is Anthem Biosciences's return on equity?

Ans. Anthem Biosciences reported a return on equity of 19.45%, which is above the 12.90% average of its named peers in this comparison.

Should I invest in Anthem Biosciences based on its sector position?

Ans. Anthem Biosciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.